CINCINNATI, Mar 24, 2003 (BUSINESS WIRE) -- Meridian Bioscience, Inc.,
(Nasdaq:VIVO) today announced the publication, in The American Journal of
Gastroenterology, of an important multicenter clinical study of Meridian's
Premier Platinum HpSA(R) Test (HpSA) conducted in leading childrens' hospitals
in Japan. The study, performed by the Japanese Pediatric HpSA Study Group, was
designed to evaluate the diagnostic accuracy of Meridian's HpSA test in Japanese
children. Based upon the results of this study, the authors concluded that the
HpSA test is an accurate test for the detection of H. pylori infection in all
age groups of children. (American Journal of Gastroenterology 2003; 98: 296-300
(C) 2003 by American College of Gastroenterology).
Helicobacter pylori (H. pylori) bacterial infection has been associated with
peptic ulcer disease since the early 1980s and it is estimated that over
one-half of the world's population is infected with H. pylori. Since that time,
H. pylori has also been associated with chronic gastritis and gastric cancer.
More recent studies are investigating this bacterium's role in conditions such
as iron deficiency anemia, physiologic development, and allergic reactions. In
the U.S. alone, the annual costs of peptic ulcer disease exceed $6 billion.
The Premier Platinum HpSA Test, developed by Meridian Bioscience, is economical
and easy to perform and was designed to expand physician and patient access to
H. pylori testing. This diagnostic test, used in conjunction with cost-efficient
eradication therapies, enables better patient management and improved cost
efficiency for healthcare systems worldwide.
Commenting, John A. Kraeutler, President and Chief Operating Officer stated, "We
are pleased that our patented Premier HpSA Test continues to be accepted
worldwide as the test of choice for accurate and rapid diagnosis of H. pylori
infection. We would like to offer our appreciation to the authors of this
important publication for their high-quality research and to the medical
professionals that continue to examine the relationship of H. pylori infection
in acute and chronic diseases."
FORWARD LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from
civil litigation for forward looking statements accompanied by meaningful
cautionary statements. These statements identify important factors that could
cause actual results to differ materially from those that might be projected.
Meridian's continued growth depends, in part, on its ability to introduce into
the marketplace enhancements of existing products or new products that
incorporate technological advances, meet customer requirements and respond to
products developed by Meridian's competition. While Meridian has introduced a
number of internally-developed products, there can be no assurance that it will
be successful in the future in introducing such products on a timely basis.
Ongoing consolidations of reference laboratories and formation of multi-hospital
alliances may cause adverse changes to pricing and distribution. Costs and
difficulties in complying with laws and regulations administered by the United
States Food and Drug Administration can result in unanticipated expenses and
delays and interruptions to the sale of new and existing products. One of
Meridian's main growth strategies is the acquisition of companies and product
lines. There can be no assurance that additional acquisitions will be
consummated or that, if consummated, will be successful and the acquired
businesses successfully integrated into Meridian's operations.
Meridian is a fully integrated life science company that manufactures, markets
and distributes a broad range of innovative diagnostic test kits, purified
reagents and related products and offers biopharmaceutical enabling
technologies. Utilizing a variety of methods, these products provide accuracy,
simplicity and speed in the early diagnosis and treatment of common medical
conditions, such as gastrointestinal, viral, urinary and respiratory infections.
All Meridian products are used outside of the human body and require little or
no special equipment. The Company's products are designed to enhance patient
well-being while reducing the total outcome costs of healthcare. Meridian has
strong market positions in the areas of gastrointestinal and upper respiratory
infections, serology, parasitology and fungal disease diagnosis. In addition,
Meridian is a supplier of rare reagents and specialty biologicals. The Company
markets its products to hospitals, reference laboratories, research centers,
veterinary testing centers and physician offices in more than 60 countries
around the world. The Company's shares are traded through Nasdaq's National
Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Meridian Bioscience, Inc.
John A. Kraeutler, 513/271-3700
Copyright (C) 2003 Business Wire. All rights reserved.